Major trial launches for First-Ever chikungunya vaccine

NCT ID NCT07467707

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Bavarian Nordic Source: ClinicalTrials.gov ↗

Summary

This is a large, late-stage study to test a new vaccine designed to prevent chikungunya, a painful mosquito-borne illness. It will enroll over 6,000 healthy adolescents and adults who have not had chikungunya before. The main goal is to see if the vaccine safely prevents people from getting sick with the disease compared to a placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Kamphaeng Phet Provincial Hospital

    Kamphaeng Phet, Changwat Kamphaeng Phet, 62000, Thailand

    Contact

  • Songklanagarind hospital, Prince of Songkla University (PSU)

    Hat Yai, Changwat Songkhla, 90110, Thailand

    Contact

  • WRAIR-AFRIMS Philippines, Cebu (WRAIR-APC)

    Cebu City, Cebu, 6000, Philippines

    Contact

Conditions

Explore the condition pages connected to this study.